Golden has been acquired by ComplyAdvantage.Read about it here ⟶

Synklino

Synklino is an immunotoxin drug for cytomegalovirus in transplant recipients founded in 2017 by Thomas Kledal Ph.D., MBA , Mads Jeppesen Ph.D. and Mette Rosenkilde MD, Ph.D. .

Overview Structured Data Issues Contributors Activity

synklino.com

Is a

Organization

Company

Company attributes

Industry

Biomedical engineering

Organ transplantation

...

Location

‌

Lyngby, Hovedstaden, Denmark

Charlottenlund

B2X

B2B

CEO

Founder

‌

Thomas Kledal Ph.D., MBA

‌

Mads Jeppesen Ph.D.

‌

Mette Rosenkilde MD, Ph.D.

Pitchbook URL

pitchbook.com/profiles...433845-01

Email Address

info@synklino.com0

Phone Number

+45201216560

Full Address

Rådhusvej 13 2920 Charlottenlund Denmark0

Investors

Maj Invest

Eir Ventures

Founded Date

2017

Total Funding Amount (USD)

79,700,000

Latest Funding Round Date

June 9, 2022

Business Model

Commerce

Latest Funding Type

COO

Country

Other attributes

Latest Funding Round Amount (USD)

31,700,000

No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more companies like Synklino

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.

Open Query Tool

Access by API